Populations from two medieval sites in Central Poland, Stary Brześć Kujawski-4 (SBK-4) and Gruczno, represented high level of lactase persistence (LP) as followed by the LCT-13910*T allele's presence (0.86 and 0.82, respectively). It was twice as high as in contemporaneous Cedynia (0.4) and Śródka (0.43), both located outside the region, higher than in modern inhabitants of Poland (0.51) and almost as high as in modern Swedish population (0.9). In an attempt to explain the observed differences its frequency changes in time were followed between the Middle Neolithic and the Late Middle Ages in successive dairying populations on a relatively small area (radius ∼60km) containing the two sites. The introduction of the T allele to Kuyavia 7.4 Ka BP by dairying LBK people is not likely, as suggested by the obtained data. It has not been found in any of Neolithic samples dated between 6.3 and 4.5 Ka BP. The identified frequency profile indicates that both the introduction and the beginning of selection could have taken place approx. 4 millennia after first LBK people arrived in the region, shifting the value of LP frequency from 0 to more than 0.8 during less than 130 generations. We hypothesize that the selection process of the T allele was rather rapid, starting just after its introduction into already milking populations and operated via high rates of fertility and mortality on children after weaning through life-threatening conditions, favoring lactose-tolerant individuals. Facing the lack of the T allele in people living on two great European Neolithization routes, the Danubian and Mediterranean ones, and based on its high frequency in northern Iberia, its presence in Scandinavia and estimated occurrence in Central Poland, we propose an alternative Northern Route of its spreading as very likely. None of the successfully identified nuclear alleles turned out to be deltaF508 CFTR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390234PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122384PLOS

Publication Analysis

Top Keywords

lbk people
12
middle neolithic
8
middle ages
8
dairying lbk
8
central poland
8
high
5
hunting lct-13910*t
4
allele
4
lct-13910*t allele
4
middle
4

Similar Publications

Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways.

View Article and Find Full Text PDF

Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.

Neurology

December 2024

From the Departments of Neurology (R.R., K.A.O.N., R.K., A.S., L.B.K.), Population Health (R.K.), and Radiology (J.T.L.), New York University Grossman School of Medicine, New York; Department of Neurology (R.R.), Weill Cornell Medical Center, New York; Department of Biostatistics (R.A.B.), New York University School of Global Public Health, New York; icometrix (T.B.), Leuven, Belgium; Department of Pediatrics (M.M.-S.), Baylor College of Medicine, Houston, TX; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital (M.M.-S.), Houston; and Department of Pediatrics (H.D.M., M.W.), University of Utah, Salt Lake City.

Background And Objectives: Accumulating evidence points to worse clinical outcomes among adults with multiple sclerosis (MS) belonging to minority or poverty-affected groups. By contrast, little is known about the outcomes of these populations with pediatric-onset MS (POMS). Individuals with POMS represent 5% of the MS population and are more racially diverse yet have been understudied regarding socioeconomic environment or characteristics.

View Article and Find Full Text PDF

Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.

Neurology

December 2024

From the Department of Neurology (E. Wilson), Cincinnati Children's Hospital, OH; Department of Neurology (E. Wilson, M.P.G., L.A.B.), Boston Children's Hospital, MA; Department of Pediatric Neurology (E. Wilson, K.C., T.C.), Massachusetts General Hospital, Boston; Department of Pediatrics (H.D.M., B.J.B., M.W., T.C.C., J.W.R.), University of Utah, Salt Lake City; Department of Neurology (M. Rodriguez, J.-M.T.), Mayo Clinic, Rochester, MN; Department of Neurology (M. Rensel, A.W.A.), Cleveland Clinic, OH; Department of Neurology (L.B.K.), New York University Medical Center, NY; Department of Neurology (T.E.L., K.S.F., N.M.S.), Texas Children's Hospital, Houston; Department of Neurology (T.L.S.), Children's Hospital Colorado, Aurora; Department of Neurology (S.S.M.), Washington University in St. Louis, MO; Department of Neurology (E. Waubant, A.V.), UCSF Weill Institute for Neurosciences, University of California San Francisco; and Department of Neurology (Y.S.W., J.M.N.), University of Alabama at Birmingham.

Article Synopsis
  • The study investigates how social determinants of health (SDOH) impact pediatric-onset multiple sclerosis (POMS), particularly in terms of adverse SDOH frequency and their effects on treatment and outcomes.
  • Researchers conducted a retrospective analysis of data from the United States Network of Pediatric MS Centers, focusing on various demographic and clinical outcomes related to SDOH hardships.
  • Findings indicated that 66% of participants faced social hardships, which influenced factors such as age at symptom onset, steroid treatment likelihood, study attrition risk, and overall health scores.
View Article and Find Full Text PDF

Background: Patients hospitalised for COVID-19 are at risk for multiorgan failure and death. Sodium-glucose co-transporter-2 (SGLT2) inhibitors provide cardiovascular and kidney protection in patients with cardiometabolic conditions and could provide organ protection during COVID-19. We aimed to investigate whether SGLT2 inhibitors can reduce the need for organ support in patients hospitalised for COVID-19.

View Article and Find Full Text PDF

Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.

Alzheimers Dement

October 2024

Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, Devon, UK.

Article Synopsis
  • The study examined DNA methylation patterns in blood samples related to 15 key biomarkers of Alzheimer's disease, focusing on neuroinflammation and neurodegeneration effects.
  • Using 885 samples from the EMIF-AD study, researchers identified significant differential methylation connected to CSF levels of YKL-40 and neurofilament light chain (NfL).
  • Findings suggest a link between YKL-40 DNA methylation and genetic variants, with implications for understanding how DNA methylation influences protein levels relevant to Alzheimer's disease.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!